Pibrentasvir
new
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 528903

CAS#: 1353900-92-1 (free)

Description: Pibrentasvir, also known as ABT-530, is a protease inhibitor potentially for the treatment of HCV infection.


Price and Availability

Size Price Shipping out time Quantity
25mg USD 150 Same day
50mg USD 250 Same day
100mg USD 450 Same day
200mg USD 750 Same day
500mg USD 1250 Same day
1g USD 1950 Same day
2g USD 3250 Same day
5g USD 4350 Same day
10g USD 6950 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-10-22. Prices are subject to change without notice.

Pibrentasvir, purity > 98%, is in stock. The same day shipping out after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 528903
Name: Pibrentasvir
CAS#: 1353900-92-1 (free)
Chemical Formula: C57H65F5N10O8
Exact Mass: 1112.4907
Molecular Weight: 1113.2
Elemental Analysis: C, 61.50; H, 5.89; F, 8.53; N, 12.58; O, 11.50


Related CAS #: 1821461-48-6 (butanamine hydrate)   1353900-92-1 (free)    

Synonym: ABT-530; ABT530; ABT 530, A-1325912; A 1325912; A1325912; A-1325912.0; A 1325912.0; A1325912.0; Pibrentasvir.

IUPAC/Chemical Name: dimethyl ((2S,2'S,3R,3'R)-((2S,2'S)-(((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)pyrrolidine-2,5-diyl)bis(6-fluoro-1H-benzo[d]imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methoxy-1-oxobutane-1,2-diyl))dicarbamate

InChi Key: VJYSBPDEJWLKKJ-NLIMODCCSA-N

InChi Code: InChI=1S/C57H65F5N10O8/c1-29(77-3)49(67-56(75)79-5)54(73)70-19-7-9-47(70)52-63-41-25-35(37(59)27-43(41)65-52)45-15-16-46(72(45)34-23-39(61)51(40(62)24-34)69-21-17-32(18-22-69)31-11-13-33(58)14-12-31)36-26-42-44(28-38(36)60)66-53(64-42)48-10-8-20-71(48)55(74)50(30(2)78-4)68-57(76)80-6/h11-14,23-30,32,45-50H,7-10,15-22H2,1-6H3,(H,63,65)(H,64,66)(H,67,75)(H,68,76)/t29-,30-,45-,46-,47+,48+,49+,50+/m1/s1

SMILES Code: FC1=CC=C(C=C1)C2CCN(CC2)C3=C(C=C(C=C3F)N4[C@H](CC[C@@H]4C5=C(F)C=C6NC([C@@H]7CCCN7C([C@@H](NC(OC)=O)[C@H](OC)C)=O)=NC6=C5)C8=C(C=C9C(N=C([C@@H]%10CCCN%10C([C@@H](NC(OC)=O)[C@H](OC)C)=O)N9)=C8)F)F


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Safety Data Sheet (SDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Mensa FJ, Lovell S, Pilot-Matias T, Liu W. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection. Future Microbiol. 2019 Jan;14:89-110. doi: 10.2217/fmb-2018-0233. Epub 2018 Nov 30. Review. PubMed PMID: 30499343.

2: Clinical Review Report: Glecaprevir / Pibrentasvir (Maviret): (AbbVie Corporation): Indication: Hepatitis C genotype 1 to 6 [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Feb. Available from http://www.ncbi.nlm.nih.gov/books/NBK533768/ PubMed PMID: 30462453.

3: Pharmacoeconomic Review Report: Glecaprevir / Pibrentasvir (Maviret): (AbbVie Corporation): Indication: Hepatitis C genotype 1 to 6 [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Feb. Available from http://www.ncbi.nlm.nih.gov/books/NBK533682/ PubMed PMID: 30462452.

4: CADTH Canadian Drug Expert Committee Recommendation: Glecaprevir / Pibrentasvir (Maviret — Abbvie Corporation): Indication: Chronic hepatitis C virus infection [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jan. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK533338/ PubMed PMID: 30457786.

5: Glecaprevir/pibrentasvir for hepatitis C. Aust Prescr. 2018 Oct;41(5):169-170. doi: 10.18773/austprescr.2018.050. Epub 2018 Aug 2. Review. PubMed PMID: 30410216; PubMed Central PMCID: PMC6202291.

6: Pearlman BL, Hinds AE. Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir. Aliment Pharmacol Ther. 2018 Nov;48(9):914-923. doi: 10.1111/apt.14977. Epub 2018 Oct 4. Review. PubMed PMID: 30288771.

7: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK525500/ PubMed PMID: 30222292.

8: Nehra V, Rizza SA, Temesgen Z. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection in adults. Drugs Today (Barc). 2018 Jul;54(7):407-421. doi: 10.1358/dot.2018.54.7.2828188. Review. PubMed PMID: 30090878.

9: Abutaleb A, Kottilil S, Wilson E. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. Hepatol Int. 2018 May;12(3):214-222. doi: 10.1007/s12072-018-9873-y. Epub 2018 May 29. Review. PubMed PMID: 29845496; PubMed Central PMCID: PMC6436099.

10: Carrion AF, Martin P. Glecaprevir + pibrentasvir for treatment of hepatitis C. Expert Opin Pharmacother. 2018 Mar;19(4):413-419. doi: 10.1080/14656566.2018.1444030. Epub 2018 Mar 7. Review. PubMed PMID: 29465262.

11: Hubbard H, Lawitz E. Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C. Expert Rev Gastroenterol Hepatol. 2018 Jan;12(1):9-17. doi: 10.1080/17474124.2018.1411802. Epub 2017 Dec 5. Review. PubMed PMID: 29187007.

12: Lamb YN. Glecaprevir/Pibrentasvir: First Global Approval. Drugs. 2017 Oct;77(16):1797-1804. doi: 10.1007/s40265-017-0817-y. Review. PubMed PMID: 28929412.